Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Richard, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa, talks about the changes MCO-010 treatment has made in his life.
Hear how a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa feels about his experience two years after being enrolled in the study.
Hear what a Stargardt Macular Degeneration patient in our STARLIGHT Clinical Trial has to say about her experience.

Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

Nanoscope News & Events
-
Nanoscope Therapeutics to Present at the 4th Annual Gene Therapy for Ophthalmic Disorders SummitSeptember 28, 2023
-
Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical OfficerSeptember 21, 2023
-
Nanoscope Therapeutics Unveils Clinical Trial Results for MCO-010 in Treating Stargardt DiseaseAugust 9, 2023
-
Nanoscope Therapeutics to Present at the 2023 American Society of Retina Specialists (ASRS) Annual Scientific MeetingJuly 21, 2023
-
Nanoscope Therapeutics to Participate in the Baird 2023 Biotech Discovery SeriesJune 12, 2023
-
Nanoscope Therapeutics Announces Participation in Upcoming ConferencesJune 8, 2023
-
Nanoscope Therapeutics to Present at the BIO International ConventionJune 5, 2023
-
Nanoscope Therapeutics Announces Presentations at the World Orphan Drug CongressMay 22, 2023